<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="503">
  <stage>Registered</stage>
  <submitdate>10/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <actrnumber>ACTRN12605000401651</actrnumber>
  <trial_identification>
    <studytitle>Assessment of the safety and efficacy of fondaparinux as an anticoagulant in haemofiltraion in patients with acute renal failure</studytitle>
    <scientifictitle>Assessment of the safety and efficacy of fondaparinux as an anticoagulant in haemofiltraion in patients with acute renal failure</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Patients requiring haemofiltration for acute renal failure.</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The active group will be given ondaparinux for anticoagulation for the first filter only during their course of haemofiltration. 
 The decision to commence or cease haemofiltraion will remain with treating physician.</interventions>
    <comparator>The control group will have enoxaparin for haemofilter anticoagulation which is the current practice in the Royal Melbourne Hispital Intensive Care Unit. </comparator>
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The study will evaluate  the duration of filter patency using fondaparinux as an anticoagulant in haemofiltration and compare this to current standard haemofilter anticoagulation with enoxaparin.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the incidence of complications, primarily bleeding, with fondaparinux compared to enoxaparin in this setting.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>The study will be conducted in the Intensive Care Unit at The Royal Melbourne Hospital and will aim to include patients who fulfill the following criteria: 1.Adult patients admitted to the ICU with an expected stay of more than 48h. 2.Patients who require continuous renal replacement therapy. 3.Patients who consent or if the patient is incompetent, the next-of-kin who consent, to inclusion in the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.Patients who are pregnant. 2.Patients with a contra-indication to anticoagulation for pre-existing bleeding diathesis. 3.Patients or next-to-kin who do not consent to study inclusion.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sequentailly numbered opaque envelopes</concealment>
    <sequence>A computer generated randomisation matrix.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>4/06/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Intensive Care Unit, RMH</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Intensive Care Research department Funding, Royal Melbourne Hospital</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Belinda Howe</name>
      <address>Intensive Care Unit
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61 3 93427710</phone>
      <fax>+61 3 93428812</fax>
      <email>belinda.howe@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr M Robertson</name>
      <address>Intensive Care Unit
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61 3 93427441</phone>
      <fax>+61 3 93428812</fax>
      <email>megan.robertson@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>